In the first experiment, where the two different isotypes (huIgG1 and muIgG2a) of anti-CCR4 9E10J antibody were compared, the highest anti-tumor activity was observed for the chimeric antibody variant comprising the murine IgG2a Fc portion. This evidence concerns the gene CCR4 and neoplasm.